All In MedTech

Device Trial Radar · NCT02108496

Verifying the Effectiveness of the NUsurface® System

The VENUS Clinical Study (Verifying the Effectiveness of the NUsurface® System) A Multi-centered, Prospective, Randomized, Interventional, Superiority Clinical Study

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 337 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

337

Actual

Start

Jul 2014

Primary completion

Jun 2021

Study completion May 3, 2022

Sponsor

Lead sponsor
Phoenix KineticsNot on our public-company list
Sponsor type
Industry
First posted
Apr 9, 2014

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 30 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The NUsurface® Meniscus Implant Randomized Study is a multi-center, prospective randomized, interventional clinical trial to test the hypothesis that the NUsurface implant is superior to the non-surgical standard of care in treating the target population.The rationale for performing this clinical study is to gather clinical data to evaluate the safety and effectiveness of the NUsurface device compared to the Standard of Care.

Conditions

  • Meniscectomy
  • Osteoarthritis

Interventions

  • NUsurface® Meniscus ImplantDevice

    The NUsurface Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.

  • NSAID's and Non-surgical Treatment OptionsDrug

    Non-prescription drugs, creams, vitamins, and supplements, Prescription or Non-Prescriptions NSAIDs, Non-weight bearing and/or open chain physical therapy or self-administered exercise

  • Intra-Articular Injections with CorticosteroidsDrug

    Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).

  • Intra-Articular Injections with Hyaluronic Acid (HA)Drug

    Intra-articular injection of a hyaluronic acid treatment, such as SYNVISC® HA Injections.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Success Composite EndpointTime frame: 2 years
  2. Automatic Study FailureTime frame: 2 Years
  3. KOOS SuccessTime frame: 2 years

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • OrthoIndy

    Indianapolis, Indiana

  • Brigham and Woman's Hospital

    Boston, Massachusetts

  • New England Baptist Hospital

    Roxbury Crossing, Massachusetts

6 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.